Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAHID RAFIQ

Allopathic & Osteopathic Physicians Neuromusculoskeletal Medicine & OMM

NPI
1447214549
CMS profile
338035
Location
FREDERICK, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,031.42

122 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,031.42 122

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAHID RAFIQ

NPI 1447214549 · CMS profile ID 338035

Allopathic & Osteopathic Physicians / Neuromusculoskeletal Medicine & OMM

FREDERICK, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAHID RAFIQ, NPI 1447214549, CMS profile ID 338035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SHAHID RAFIQ, NPI 1447214549, CMS profile ID 338035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SHAHID RAFIQ, NPI 1447214549, CMS profile ID 338035, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

122 matching records · $2,031.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 122 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–122 of 122.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $17.3402/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795751453 CMS
E.R. Squibb & Sons, L.L.C. $13.5802/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783574337 CMS
AbbVie Inc. $13.8302/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795751447 CMS
Neurelis, Inc. $17.6302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842876789 CMS
Novartis Pharmaceuticals Corporation $1.5802/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813181975 CMS
Sunovion Pharmaceuticals Inc. $22.4002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821591667 CMS
Sunovion Pharmaceuticals Inc. $22.4002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821591673 CMS
E.R. Squibb & Sons, L.L.C. $15.8202/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783574327 CMS
Allergan, Inc. $6.0202/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792914335 CMS
AbbVie Inc. $17.9502/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795751435 CMS
AbbVie Inc. $4.3802/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795751441 CMS
Novartis Pharmaceuticals Corporation $12.8601/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813181979 CMS
AbbVie Inc. $14.4101/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795751429 CMS
Neurelis, Inc. $15.1801/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842876785 CMS
AbbVie Inc. $2.2101/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795751423 CMS
Amgen Inc. $19.3901/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825780441 CMS
Allergan, Inc. $13.5801/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792914333 CMS
Teva Pharmaceuticals USA, Inc. $20.2901/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839698583 CMS
Allergan, Inc. $13.8201/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792914331 CMS
Sunovion Pharmaceuticals Inc. $22.9301/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821579533 CMS
Amgen Inc. $27.4301/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825780437 CMS
E.R. Squibb & Sons, L.L.C. $15.0401/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783574321 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,882.31 134
PY2020 $1,426.68 88
PY2021 $2,031.42 122
PY2022 $3,908.02 109
PY2023 $1,693.85 97
PY2024 $1,798.04 90
PY2025 $1,748.75 95

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $591,294.79 50
PY2024 Principal investigator $236,963.75 13
PY2023 Principal investigator $139,146.77 9
PY2022 Principal investigator $9,746.21 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $801.09 12/24/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288760
Principal investigator 1 Janssen Research & Development, LLC $1,789.00 12/24/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228077
Principal investigator 1 Janssen Research & Development, LLC $8,685.00 12/17/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228130
Principal investigator 1 Novartis Pharmaceuticals Corporation $60.00 12/01/2025 Non-covered Recipient Entity
COMPREHENSIVE NEUROLOGY SERVICES PA
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190311335
Principal investigator 1 Janssen Research & Development, LLC $13,552.00 11/14/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228114
Principal investigator 1 Ipsen Innovation $68.37 10/27/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288756
Principal investigator 1 Ipsen Innovation $801.09 10/27/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288758
Principal investigator 1 Janssen Research & Development, LLC $3,524.00 10/20/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228086
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,841.07 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE NEUROLOGY SERVICES PA
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311331
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,653.00 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE NEUROLOGY SERVICES PA
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190311337
Principal investigator 1 Janssen Research & Development, LLC $6,061.00 09/19/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228122
Principal investigator 1 Ipsen Innovation $300.00 09/02/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288750
Principal investigator 1 Ipsen Innovation $180.00 09/02/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288752
Principal investigator 1 Ipsen Innovation $300.00 09/02/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288754
Principal investigator 1 Ipsen Innovation $1,662.81 08/28/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288746
Principal investigator 1 Ipsen Innovation $801.09 08/28/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288748
Principal investigator 1 Janssen Research & Development, LLC $3,639.00 08/20/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228092
Principal investigator 1 Ipsen Innovation $801.09 07/28/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288742
Principal investigator 1 Janssen Research & Development, LLC $3,526.00 07/28/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228138
Principal investigator 1 Ipsen Innovation $450.00 07/22/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288738
Principal investigator 1 Ipsen Innovation $150.00 07/22/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288740
Principal investigator 1 Ipsen Innovation $90.00 07/22/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288744
Principal investigator 1 Ipsen Innovation $801.09 06/30/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288734
Principal investigator 1 Ipsen Innovation $1,233.24 06/30/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288736
Principal investigator 1 Janssen Research & Development, LLC $8,440.00 06/13/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228107
Principal investigator 1 Janssen Research & Development, LLC $4,086.00 05/16/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228152
Principal investigator 1 Ipsen Innovation $801.09 04/28/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288722
Principal investigator 1 Ipsen Innovation $2,151.72 04/28/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288728
Principal investigator 1 Ipsen Innovation $1,722.15 04/28/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288730
Principal investigator 1 Ipsen Innovation $824.31 04/28/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288732
Principal investigator 1 Ipsen Innovation $90.00 04/18/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288724
Principal investigator 1 Ipsen Innovation $150.00 04/18/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288726
Principal investigator 1 Janssen Research & Development, LLC $1,154.00 04/18/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228159
Principal investigator 1 Ipsen Innovation $481.54 03/31/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288720
Principal investigator 1 Janssen Research & Development, LLC $5,877.00 03/19/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228146
Principal investigator 1 Ipsen Innovation $90.00 02/26/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288714
Principal investigator 1 Ipsen Innovation $150.00 02/26/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288716
Principal investigator 1 Ipsen Innovation $150.00 02/26/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288718
Principal investigator 1 Janssen Research & Development, LLC $3,285.00 02/19/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175230410
Principal investigator 1 Ipsen Innovation $90.00 02/17/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288708
Principal investigator 1 Ipsen Innovation $150.00 02/17/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288710
Principal investigator 1 Ipsen Innovation $150.00 02/17/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288712
Principal investigator 1 Ipsen Innovation $68.37 01/31/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288706
Principal investigator 1 Novartis Pharmaceuticals Corporation $120.00 01/31/2025 Non-covered Recipient Entity
CLINRE COMPREHENSIVE NEUROLOGY
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190314135
Principal investigator 1 Janssen Research & Development, LLC $5,446.00 01/17/2025 Non-covered Recipient Entity
Comprehensive Nrlgy Svcs
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175228101
Principal investigator 1 Ipsen Innovation $180.00 01/16/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288700
Principal investigator 1 Ipsen Innovation $300.00 01/16/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288702
Principal investigator 1 Ipsen Innovation $300.00 01/16/2025 Non-covered Recipient Entity
Comprehensive Neurology Services, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288704
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,635.02 01/16/2025 Non-covered Recipient Entity
CLINRE COMPREHENSIVE NEUROLOGY
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190312229
Principal investigator 1 Novartis Pharmaceuticals Corporation $447,632.65 01/02/2025 Non-covered Recipient Entity
COMPREHENSIVE NEUROLOGY SERVICES PA
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311333